are now a part of the new and improved


Dermwire News

News | April 8, 2019

AIM at Melanoma Opens Melanoma Tissue Bank in the US

AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six...

Read More

News | April 16, 2019

Maine Gets SUNucated

Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery...

Read More

News | April 15, 2019

A Conserved Stress Response May Fuel Resistance to BRAF Inhibitors in Melanoma

Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to drugs that target the BRAF protein and its signaling pathway. Their study was published online in the journal Cancer...

Read More

News | March 28, 2019

BTL to Launch Small Emsculpt Applicator for Arms, Thighs, Calves

BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and...

Read More
Thumbnail for gvhiwine
Play Button

Updates from Principia, Sebacia, and Candela

Series: DermWire TV | March 21, 2019

Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.

Watch Video


The Latest News


View more